Category: Press Release - Page 2

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Post published:May 25, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Post published:May 22, 2023
Post category:Press Release

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Post published:May 19, 2023
Post category:Press Release

Read more about the article Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

Post published:May 19, 2023
Post category:Press Release

FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON

Post published:May 17, 2023
Post category:Press Release

Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market

Post published:May 17, 2023
Post category:Press Release

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Post published:May 17, 2023
Post category:Press Release

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Post published:May 13, 2023
Post category:Press Release

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

Post published:May 12, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Post published:May 11, 2023
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON

Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.